Holen Sie sich die Stockscreener-App
59.46
0.15%
-0.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$59.55
Offen:
$59.97
24-Stunden-Volumen:
6.49M
Relative Volume:
0.57
Marktkapitalisierung:
$121.42B
Einnahmen:
$48.48B
Nettoeinkommen (Verlust:
$7.27B
KGV:
16.69
EPS:
3.5626
Netto-Cashflow:
$11.91B
1W Leistung:
+4.32%
1M Leistung:
+1.12%
6M Leistung:
+28.56%
1J Leistung:
+26.43%
1-Tages-Spanne:
$59.25
$60.25
1-Wochen-Bereich:
$57.08
$60.25
52-Wochen-Spanne:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.46 | 121.61B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Meiji Yasuda Asset Management Co Ltd. Purchases 55,355 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Tempus AI, Inc. (TEM) and Bristol Myers Announce a Strategic Partnership - Insider Monkey
Bristol-Myers Squibb Company stock (US0897961004): Analyst moves and dividend draw fresh attention - AD HOC NEWS
BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung - GlobeNewswire Inc.
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - BioSpace
HALL CAPITAL MANAGEMENT CO INC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
ETFs Investing in Bristol-Myers Squibb Company Stocks - TradingView
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid - BioPharma Dive
Bristol Myers Squibb Partners With Anthropic to Deploy Claude Across Global Operations - Digital Health News
Why so many pharmaceutical giants want to invest billions in Houston - The Business Journals
BMS expands AI push with Anthropic partnership - The Pharma Letter
PNC Financial Services Group Inc. Sells 225,894 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Hengrui, BMS deal watershed moment for China biotech - BioWorld News
Biopharma Giant Bristol Myers Squibb Partners with Anthropic for AI Integration - GuruFocus
Anthropic And OpenAI--Building Different Competitive Advantages - Benzinga
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery - Benzinga
Bristol Myers deepens AI investment with Anthropic deal - BioPharma Dive
Anthropic signs enterprise AI deal with Bristol Myers Squibb - MobiHealthNews
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows - Fierce Pharma
Bristol Myers Squibb Expands AI Push With Anthropic’s Claude for 30,000 Employees - citybiz
Bristol Myers to deploy Anthropic’s Claude AI model to accelerate drug discovery - The News International
Exclusive | Bristol-Myers Squibb Brings Anthropic’s Claude to 30,000 of Its Staff - WSJ
Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank - The Globe and Mail
Bristol Myers to deploy Anthropic’s Claude AI model to speed up drug discovery By Reuters - Investing.com
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery - Reuters
Bristol Myers Squibb partners with Anthropic to deploy Claude AI By Investing.com - Investing.com Canada
Bristol Myers, Anthropic to partner on Claude use - Breakingthenews.net
How Bristol Myers will use Anthropic’s Claude to speed medicines to patients - Stock Titan
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
TiNivo-2 Completion: What Bristol-Myers Squibb’s Kidney Cancer Trial Means for Investors - TipRanks
Bristol-Myers Squibb Company stock (US0897961004): oncology pipeline and US expansion keep the pharm - AD HOC NEWS
Pharma giant considers Houston for $1B manufacturing campus - InnovationMap
Resona Asset Management Co. Ltd. Sells 21,761 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law - Benzinga
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Yahoo Finance
Bristol Myers Squibb eyes $1B drug manufacturing campus in Generation Park - Community Impact | News
SCOTUS rejects Medicare drug price negotiation appeals by drugmakers - Modern Healthcare
Bristol-Myers Squibb Company stock (US0897961004): cancer drug news and pipeline focus after earning - AD HOC NEWS
Bristol-Myers Squibb Made Its Pipeline Case at BofA. Now Comes the Proof. - TIKR.com
BMY: Bristol Myers Squibb and Hengrui Pharma Strike $15.2B Licen - GuruFocus
Pharmaceutical giant eyes Houston for $1 billion campus - Chron
MCDONALD PARTNERS LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Vestcor Inc's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Another pharma giant eyes Houston for $1B plant with hundreds of jobs possible - KHOU
Bristol Myers Squibb eyes Houston for $1B pharmaceutical plant - The Business Journals
Biopharma Collaboration: Bristol Myers Squibb Partners with Heng - GuruFocus
Bristol Myers Squibb touts pipeline gains as shareholders back board at annual meeting - MSN
Bristol Myers Squibb partners with Hengrui Pharma to develop and test drugs early in China. - Pluang
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development - Intellectia AI
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape - Oncodaily
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
2.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):